Climb Bio Business Summary

Climb Bio, Inc. (CLYM) is a clinical-stage biotechnology company that generates value through the development and future commercialization of monoclonal antibodies targeting immune-mediated and B-cell-driven diseases. The company’s primary business segments are centered on its two lead clinical programs: budoprutug, an anti-CD19 antibody currently in Phase 2 trials for primary membranous nephropathy (pMN) and Phase 1b/2a for immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE); and CLYM116, an anti-APRIL antibody targeting IgA nephropathy (IgAN). As a pre-revenue entity, Climb Bio relies on a robust cash position—approximately $160.7 million as of year-end 2025—to fund operations through anticipated 2026 data readouts. Direct competitors include Amgen (Uplizna), Biohaven, and Argenx, with Climb Bio positioning itself as a specialist in high-precision B-cell depletion and renal-focused immunology. The company is led by President and CEO Dr. Aoife Brennan, who previously served as CEO of Synlogic and held senior leadership roles at Biogen. The executive team features deep industry pedigree, including CFO Dr. Susan Altschuller (formerly of ImmunoGen and Alexion), Chief Medical Officer Dr. Edgar Charles (formerly of Bristol Myers Squibb), and Chief Business Officer Dr. Perrin Wilson. Founded by Dr. Andrew Levin and Valerie Morisset, the company is governed by a board chaired by Dr. Douglas Williams, former CEO of Codiak BioSciences. Climb Bio is backed by prominent life sciences investors, including RA Capital Management—where Dr. Levin serves as a Managing Director—alongside significant institutional support from firms such as OrbiMed and New Enterprise Associates (NEA).